320 related articles for article (PubMed ID: 25100992)
1. β-secretase inhibitor; a promising novel therapeutic drug in Alzheimer's disease.
Menting KW; Claassen JA
Front Aging Neurosci; 2014; 6():165. PubMed ID: 25100992
[TBL] [Abstract][Full Text] [Related]
2. BACE1: the beta-secretase enzyme in Alzheimer's disease.
Vassar R
J Mol Neurosci; 2004; 23(1-2):105-14. PubMed ID: 15126696
[TBL] [Abstract][Full Text] [Related]
3. Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) as a biological candidate marker of Alzheimer's disease.
Hampel H; Shen Y
Scand J Clin Lab Invest; 2009; 69(1):8-12. PubMed ID: 18609117
[TBL] [Abstract][Full Text] [Related]
4. Amyloid-β protein (Aβ) Glu11 is the major β-secretase site of β-site amyloid-β precursor protein-cleaving enzyme 1(BACE1), and shifting the cleavage site to Aβ Asp1 contributes to Alzheimer pathogenesis.
Deng Y; Wang Z; Wang R; Zhang X; Zhang S; Wu Y; Staufenbiel M; Cai F; Song W
Eur J Neurosci; 2013 Jun; 37(12):1962-9. PubMed ID: 23773065
[TBL] [Abstract][Full Text] [Related]
5. The beta-secretase, BACE: a prime drug target for Alzheimer's disease.
Vassar R
J Mol Neurosci; 2001 Oct; 17(2):157-70. PubMed ID: 11816789
[TBL] [Abstract][Full Text] [Related]
6. Stepping closer to treating Alzheimer's disease patients with BACE1 inhibitor drugs.
Yan R
Transl Neurodegener; 2016; 5():13. PubMed ID: 27418961
[TBL] [Abstract][Full Text] [Related]
7. BACE1 Cleavage Site Selection Critical for Amyloidogenesis and Alzheimer's Pathogenesis.
Zhang S; Wang Z; Cai F; Zhang M; Wu Y; Zhang J; Song W
J Neurosci; 2017 Jul; 37(29):6915-6925. PubMed ID: 28626014
[TBL] [Abstract][Full Text] [Related]
8. Beta-secretase (BACE) as a drug target for Alzheimer's disease.
Vassar R
Adv Drug Deliv Rev; 2002 Dec; 54(12):1589-602. PubMed ID: 12453676
[TBL] [Abstract][Full Text] [Related]
9. Regulation of Synaptic Amyloid-β Generation through BACE1 Retrograde Transport in a Mouse Model of Alzheimer's Disease.
Ye X; Feng T; Tammineni P; Chang Q; Jeong YY; Margolis DJ; Cai H; Kusnecov A; Cai Q
J Neurosci; 2017 Mar; 37(10):2639-2655. PubMed ID: 28159908
[TBL] [Abstract][Full Text] [Related]
10. BACE1 as a therapeutic target in Alzheimer's disease: rationale and current status.
Evin G; Hince C
Drugs Aging; 2013 Oct; 30(10):755-64. PubMed ID: 23842796
[TBL] [Abstract][Full Text] [Related]
11. Role of BACE1 in Alzheimer's synaptic function.
Das B; Yan R
Transl Neurodegener; 2017; 6():23. PubMed ID: 28855981
[TBL] [Abstract][Full Text] [Related]
12. The cysteine protease inhibitor, E64d, reduces brain amyloid-β and improves memory deficits in Alzheimer's disease animal models by inhibiting cathepsin B, but not BACE1, β-secretase activity.
Hook G; Hook V; Kindy M
J Alzheimers Dis; 2011; 26(2):387-408. PubMed ID: 21613740
[TBL] [Abstract][Full Text] [Related]
13. Highlights in BACE1 Inhibitors for Alzheimer's Disease Treatment.
Coimbra JRM; Marques DFF; Baptista SJ; Pereira CMF; Moreira PI; Dinis TCP; Santos AE; Salvador JAR
Front Chem; 2018; 6():178. PubMed ID: 29881722
[TBL] [Abstract][Full Text] [Related]
14. BACE1 structure and function in health and Alzheimer's disease.
Cole SL; Vassar R
Curr Alzheimer Res; 2008 Apr; 5(2):100-20. PubMed ID: 18393796
[TBL] [Abstract][Full Text] [Related]
15. BACE1 inhibitors: Current status and future directions in treating Alzheimer's disease.
Moussa-Pacha NM; Abdin SM; Omar HA; Alniss H; Al-Tel TH
Med Res Rev; 2020 Jan; 40(1):339-384. PubMed ID: 31347728
[TBL] [Abstract][Full Text] [Related]
16. Scope of β-Secretase (BACE1)-Targeted Therapy in Alzheimer's Disease: Emphasizing the Flavonoid Based Natural Scaffold for BACE1 Inhibition.
Das S; Sengupta S; Chakraborty S
ACS Chem Neurosci; 2020 Nov; 11(21):3510-3522. PubMed ID: 33073981
[TBL] [Abstract][Full Text] [Related]
17. BACE1 in Alzheimer's disease.
Sathya M; Premkumar P; Karthick C; Moorthi P; Jayachandran KS; Anusuyadevi M
Clin Chim Acta; 2012 Dec; 414():171-8. PubMed ID: 22926063
[TBL] [Abstract][Full Text] [Related]
18. Energy inhibition elevates beta-secretase levels and activity and is potentially amyloidogenic in APP transgenic mice: possible early events in Alzheimer's disease pathogenesis.
Velliquette RA; O'Connor T; Vassar R
J Neurosci; 2005 Nov; 25(47):10874-83. PubMed ID: 16306400
[TBL] [Abstract][Full Text] [Related]
19. Decrease in the Generation of Amyloid-β Due to Salvianolic Acid B by Modulating BACE1 Activity.
Durairajan SSK; Chirasani VR; Shetty SG; Iyaswamy A; Malampati S; Song J; Liu L; Huang J; Senapati S; Li M
Curr Alzheimer Res; 2017; 14(11):1229-1237. PubMed ID: 28413985
[TBL] [Abstract][Full Text] [Related]
20. The Basic Biology of BACE1: A Key Therapeutic Target for Alzheimer's Disease.
Cole SL; Vassar R
Curr Genomics; 2007 Dec; 8(8):509-30. PubMed ID: 19415126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
